Watch LIVE the focusIR May Investor webinar with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102

1 Nov 2023 16:30

Arix Bioscience PLC (ARIX) Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102 01-Nov-2023 / 16:30 GMT/BST


 

Arix Bioscience plc

 

Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102

 

LONDON, 1 November 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, notes that its Core Portfolio company, Sorriso Pharmaceuticals (“Sorriso”), has announced that the first subject has been dosed in the Company’s Phase 1/1b clinical program of SOR102.

 

SOR102 is a dual-acting oral biologic treatment targeting TNF and IL-23(p19) that is being developed for the treatment of inflammatory bowel disease (IBD).

 

This Phase 1 trial is a randomized, double-blind study consisting of three parts. Parts 1 and 2 will evaluate safety, tolerability and pharmacokinetics (PK) of single ascending oral doses and multiple oral doses in healthy participants. Part 3 will evaluate safety, tolerability, PK, and clinical and biological activity of multiple oral doses of SOR102 in patients with mild to severe ulcerative colitis. The trial is expected to enrol up to 60 adult participants at sites in the United Kingdom and Europe.

 

Ciara Kennedy, Ph.D. CEO at Sorriso, commented: “We are excited to initiate this first-in-human trial of SOR102 as there remains a significant need for improved therapies for patients suffering from IBD. We believe that SOR102, which addresses two validated targets and is designed to act locally within inflamed GI tissue, has the potential to be an oral first-line advanced therapy, with a superior efficacy and safety profile over existing systemically administered biologics and novel oral therapies.”

 

Robert Lyne, CEO of Arix, added: “This landmark milestone for Sorriso’s lead candidate is a very exciting next step demonstrating the Company’s translational capabilities. Sorriso is addressing an area of truly unmet need, using a highly innovative targeting approach to give hope to people suffering with severe immune-mediated diseases such as Crohn’s disease and ulcerative colitis. We look forward to seeing SOR102 develop as it advances through the Phase 1 trial.”

 

The full text from Sorriso’s announcement is reproduced below and can be accessed on the Sorriso Pharmaceuticals website here: www.sorrisopharma.com/news/

 

[ENDS]

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

 

 

About Arix Bioscience plc

Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

  

 

Sorriso Pharmaceuticals Press Release:

 

Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102

 

First-in-Human Study of Novel Oral Dual-Acting Antibody in Development for Treatment of Patients with Inflammatory Bowel Disease

 

SALT LAKE CITY, UT, UNITED STATES, November 1, 2023 /EINPresswire.com/ -- Sorriso Pharmaceuticals, a biopharmaceutical company developing novel oral antibodies in immune-mediated disease, today announced that the first subject has been dosed in the company’s Phase 1/1b clinical program of SOR102. SOR102 is a dual-acting oral biologic treatment targeting TNF and IL-23(p19) that is being developed for the treatment of inflammatory bowel disease (IBD).

 

“We are excited to initiate this first-in-human trial of SOR102 as there remains a significant need for improved therapies for patients suffering from IBD,” said Ciara Kennedy, Ph.D., chief executive officer at Sorriso. “We believe that SOR102, which addresses two validated targets and is designed to act locally within inflamed GI tissue, has the potential to be an oral first-line advanced therapy, with a superior efficacy and safety profile over existing systemically administered biologics and novel oral therapies.”

 

This Phase 1 trial is a randomized, double-blind study consisting of three parts. Parts 1 and 2 will evaluate safety, tolerability and pharmacokinetics (PK) of single ascending oral doses and multiple oral doses in healthy participants. Part 3 will evaluate safety, tolerability, PK, and clinical and biological activity of multiple oral doses of SOR102 in patients with mild to severe ulcerative colitis. The trial is expected to enroll up to 60 adult participants at sites in the United Kingdom and Europe. More information about the trial is available at www.clinicaltrials.gov, identifier NCT06080048.

 

About SOR102

SOR102 simultaneously inhibits TNF and IL-23(p19), two clinically validated drivers of IBD, providing combination therapy locally within inflamed tissue with minimal systemic exposure. This dual targeting approach may increase efficacy through simultaneous blockade of different mechanisms of IBD.

 

About Sorriso Pharmaceuticals

Sorriso Pharmaceuticals is a biopharmaceutical company advancing a pipeline of disease-modifying antibodies for the treatment of immune-mediated diseases, including Crohn’s disease and ulcerative colitis. The Sorriso platform generates potent antibodies that can be delivered orally and are designed to maintain activity throughout the human intestine.

About Sorriso Pharmaceuticals

 

For more information, please visit www.sorrisopharma.com

 


Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
ISIN:GB00BD045071
Category Code:MSCM
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:282110
EQS News ID:1762895
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
31st Mar 20215:39 pmEQSTransaction in own shares
30th Mar 20215:09 pmEQSTransaction in own shares
30th Mar 20211:02 pmEQSArix leads $152 million Series B financing for Pyxis Oncology
30th Mar 20217:00 amEQSGita Dittmar appointed as Venture Partner
29th Mar 20215:14 pmEQSTransaction in own shares
29th Mar 20217:00 amEQSBoard update
26th Mar 20215:14 pmEQSTransaction in own shares
25th Mar 20214:58 pmEQSTransaction in own shares
24th Mar 20215:05 pmEQSTransaction in own shares
24th Mar 20217:00 amEQSStrategy Implementation Review
23rd Mar 20215:27 pmEQSTransaction in own shares
22nd Mar 20215:57 pmEQSTransaction in own shares
22nd Mar 202111:09 amEQSAura Biosciences announces oversubscribed $80 million financing
22nd Mar 20217:00 amEQSShare buyback programme of up to £25 million
19th Mar 20214:00 pmEQSHolding(s) in Company
15th Mar 20217:30 amEQSHardman & Co Research: Arix Bioscience (ARIX): 32% IRR since inception in 2016
15th Mar 20217:00 amEQSShare buyback programme of up to £25 million
10th Mar 20217:01 amEQSResponse to Activist Shareholder Acacia
9th Mar 20217:01 amEQSArix founds new portfolio company Twelve Bio
9th Mar 20217:01 amEQSAnnual Results for the Twelve Months ended 31 December 2020
25th Feb 20217:00 amEQSBoard Changes
15th Feb 20219:00 amEQSHolding(s) in Company
11th Feb 20217:00 amEQSNotice of Results
10th Feb 20219:00 amEQSAutolus announces pricing of public offering
5th Feb 20214:41 pmRNSSecond Price Monitoring Extn
5th Feb 20214:36 pmRNSPrice Monitoring Extension
5th Feb 20219:06 amRNSSecond Price Monitoring Extn
5th Feb 20219:00 amRNSPrice Monitoring Extension
18th Jan 20217:00 amEQSInvestment team changes
12th Jan 20217:00 amEQSHarpoon announces closing of public offering
6th Jan 20212:00 pmEQSImara reports Phase 2a clinical trial results of IMR-687 in adult patients with sickle cell disease  
6th Jan 202110:00 amEQSAutolus provides business outlook for 2021 and 2022
31st Dec 20209:00 amRNSPrice Monitoring Extension
21st Dec 20207:00 amEQSDirector Share Purchase
18th Dec 20208:00 amEQSCompletion of sale of VelosBio
11th Dec 20207:00 amEQSAtox Bio announces FDA acceptance of New Drug Application
8th Dec 20203:45 pmEQSHarpoon reports clinical progress across all pipeline development programmes
7th Dec 20205:48 pmEQSAutolus presents additional data on AUTO3 at ASH
7th Dec 20207:15 amEQSHardman & Co Research: Arix Bioscience (ARIX): Artios attracts Merck KGaA in deal up to $7bn
7th Dec 20207:01 amEQSAutolus presents positive AUTO1 data at ASH
4th Dec 20207:01 amEQSHolding(s) in Company
4th Dec 20207:00 amEQSHolding(s) in Company
3rd Dec 20209:05 amRNSSecond Price Monitoring Extn
3rd Dec 20209:00 amRNSPrice Monitoring Extension
3rd Dec 20208:01 amEQSArtios and Merck KGaA announce global strategic collaboration
12th Nov 20207:00 amEQSArix to Present at the Jefferies Virtual London Healthcare Conference
6th Nov 202012:10 pmEQSHardman & Co Research: Arix Bioscience (ARIX): Hitting the jackpot
5th Nov 20202:06 pmRNSSecond Price Monitoring Extn
5th Nov 20202:00 pmRNSPrice Monitoring Extension
5th Nov 202011:38 amEQSArix Bioscience PLC: VelosBio to be acquired by Merck for $2.75 billion

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.